Dr. Martin M. Grajower, discusses innovations to help both physicians and patients fight the silent epidemic of fatty liver disease
Dr. Martin M. Grajower, M.D., FACP, FACE, a Clinical Professor of Medicine, Division of Endocrinology, at Albert Einstein College of Medicine, Bronx, New York, joins eHealth Radio and the Health News and Technology Channels to discuss innovations to help both physicians and patients fight the silent epidemic of fatty liver disease.
Listen to interview with host Eric Michaels and guest Dr. Martin M. Grajower discuss the following:
- What are the main risk factors for nonalcoholic fatty liver disease (NAFLD)?
- Can you explain the role that obesity plays in connection with NAFLD and diabetes?
- What are the health risks associated with having NAFLD?
- At what point should endocrinologists screen for NAFLD in patients with Type 2 diabetes?
- Can you provide an example of how endocrinologists can help their patients who are at risk for liver disease?
Martin Grajower MD FACP FACE is an endocrinologist in the Bronx, New York, and is affiliated with Montefiore Medical Center and Columbia University Hospital of Physicians and Surgeons. He received his medical degree from Albert Einstein College of Medicine and has been in private practice for over 40 years. He holds the title of Clinical Professor of Medicine, Division of Endocrinology, at Albert Einstein College of Medicine.
Echosens, the developer of FibroScan®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans.